Propyl Thiouracil Market size is estimated to reach $3,000 million by 2026, growing at a CAGR of 10% over 2021-2026. Propylthiouracil are also called propranolol and is considered as an oral medication for the treatment of hyperthyroidism and also treat people with Graves ’ disease which acts by hampering the thyroid gland from producing excess thyroid hormone. Propylthiouracil is a medication that binds to thyroid peroxidase inhibitor for the conversion of iodide to iodine. Propylthiouracil is administered orally whose initial doses for adults is 300 mg daily and for pediatric patients doses is 50mg. Thiamazole are also called methimazole that reverses hyperthyroidism more quickly than propylthiouracil. Carbimazole are preferred antithyroid medicines than propylthiouracil owing to rising risk of hepatotoxicity with propylthiouracil. Growing prevalence of thyroid gland disorders and rising advanced infrastructure are the major factor driving the growth of this market. Furthermore, increasing research and development activities is set to further enhance the overall market demand for Propyl Thiouracil Market for the period 2021-2026.
Geographically, in 2020, North America dominated the Propyl Thiouracil Market owing to increasing prevalence of thyroid gland disorders and increasing development in health infrastructure.
Growing prevalence of thyroid gland disorders and rising advanced infrastructure are likely to aid in the market growth of the Propyl Thiouracil.
Detailed analysis of the Strength, Weakness, and Opportunities of the prominent players operating in the market will be provided in the Propyl Thiouracil Market report.
Increasing side effects is set to create hurdles for the Propyl Thiouracil Market.
Propyl Thiouracil Market Segment Analysis – By Type
The global Propyl Thiouracil Market based on Type can be further segmented into Thyroperoxidase Inhibitor, 5-Deiodinase Inhibitor, and Others. The Thyroperoxidase Inhibitor segment is the major segment generating revenue in 2020. This is owing to increasing uses of propyl inhibitor for the treatment of Thyroperoxidase Inhibitor increases the demand of this segment. The 5-Deiodinase Inhibitor segment is estimated to register the fastest CAGR of 5.8% for the period 2021-2026. This is owing to it is used for the synthesis of the active form of thyroid hormone that increases the use of propranolol and are increasing the growth of this segment.